A whole-genome sequencing approach shows early promise over current commercial methods for identifying more patients likely ...
Epithelial ovarian cancer (EOC) is an aggressive malignancy with limited therapeutic options. Poly(ADP-ribose) polymerase inhibitors (PARPi) have shown remarkable efficacy, especially in BRCA-mutant ...
Allarity Therapeutics, Inc. has announced a research collaboration with the Indiana Biosciences Research Institute (IBRI) to enhance their understanding of stenoparib, a dual PARP and WNT pathway ...
As treatment sequencing in ovarian cancer (OC) continues to evolve, an increasing proportion of patients acquire platinum-resistance following frontline poly(ADP-ribose) polymerase (PARP) inhibitor ...
A new study introduces an adaptive therapy approach that could optimize PARP inhibitor maintenance therapy, offering a more personalized and potentially less toxic treatment option for patients.
Clinical and Preclinical Activity of EGFR Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancer Harboring BRAF Class 3 Mutations This was a phase II multicenter trial in which refractory solid ...
Please provide your email address to receive an email when new articles are posted on . Saruparib at 60 mg/day demonstrated deep, durable responses with a high response rate and tumor reduction in ...
(A, B) Western blotting analysis of FASN and PARP1 expression in stable MDA-MB-436 cells overexpressing FASN (MDA-MB-436/FASN) and MDA-MB-231 cells with FASN knockdown (MDA-MB-231/shFASN) along with ...
The University of Texas MD Anderson Cancer Center’s Timothy Yap, M.D., doesn’t know why AstraZeneca’s PARP inhibitor saruparib seems to be spurring responses in patients who have previously not had ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results